This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
Two separate registration statements for Ironridge Global financings of micro-cap public companies declared effective by SEC so far this year
Washington, DC (PRWEB) February 21, 2014
Ironridge Global Partners, LLC, an institutional investor making direct equity investments in micro-cap public companies, announced that the U.S. Securities and Exchange Commission has declared a resale registration statement for Ironridge Global IV, Ltd. effective after a full review. This is the second registration statement declared effective by the SEC in 2014 for an Ironridge Global financing.
A resale registration statement on Form S-1 was filed by PositiveID Corporation on December 19, 2013, to register shares of common stock issuable to Ironridge Global upon conversion of 750 shares of Series F Preferred Stock that Irornidge previously purchased for cash. After two full substantive reviews by the SEC, and two amendments to provide additional disclosures concerning the issuer and various prior transactions, the registration statement was declared effective on February 6, 2014. The February 7, 2014 final Prospectus for Registration Statement No. 333-192965 is available through EDGAR on the SECs website. Ironridge Global provided a total of $5 million in funding to PositiveID to date.
In addition, a resale registration statement on Form F-3 was filed with the Securities and Exchange Commission by Genetic Technologies Limited on December 20, 2013, to register American Depository Receipts issuable to Ironridge Global BioPharma Co. upon conversion of $5 million in convertible notes that Ironridge Global BioPharma previously purchased from Genetic Technologies for $5 million in cash. That registration statement was declared effective on January 3, 2014. The January 6, 2014 final Prospectus for Registration Statement No. 333-192967 is also available on EDGAR.
The successful completion of the most recent full SEC review of an Ironridge Global financing is a tangible demonstration of the results of the funds ongoing commitment to securities compliance," commented Ironridge Global Partners managing director John C. Kirkland, The firm remains a thought leader in best practices for micro-cap financing, and looks forward to funding many future transactions for promising emerging growth companies.
About Ironridge Global
Ironridge BioPharma Co. is a division of Ironridge Global IV, Ltd. that specializes in equity investments in the life sciences sector, including companies involved in biotechnology, pharmaceuticals, medical devices and enabling technologies. Its parent Ironridge Global Partners, LLC is an institutional investor, making direct equity investments in micro-cap public companies. The fund has entered into more than 50 equity financing transactions since 2011, ranging from under a quarter million to over $15 million each. Ironridge Global seeks to be a long-term financial partner, assisting public companies in financing growth and expansion by supplying innovative funding solutions and flexible capital. For more information on Ironridge Global Partners, please visit http://www.ironridgeglobal.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of any company. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/01/prweb11537078.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.